- Home
- NPCT vs PRQR Comparison
NPCT vs PRQR Comparison
Compare NPCT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- PRQR
- Stock Information
- Founded
- NPCT 2020
- PRQR 2012
- Country
- NPCT United States
- PRQR Netherlands
- Employees
- NPCT N/A
- PRQR N/A
- Industry
- NPCT Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- PRQR Health Care
- Exchange
- NPCT Nasdaq
- PRQR Nasdaq
- Market Cap
- NPCT 304.5M
- PRQR 309.5M
- IPO Year
- NPCT N/A
- PRQR 2014
- Fundamental
- Price
- NPCT $10.53
- PRQR $2.37
- Analyst Decision
- NPCT
- PRQR Strong Buy
- Analyst Count
- NPCT 0
- PRQR 5
- Target Price
- NPCT N/A
- PRQR $7.60
- AVG Volume (30 Days)
- NPCT 107.1K
- PRQR 340.3K
- Earning Date
- NPCT 01-01-0001
- PRQR 03-12-2025
- Dividend Yield
- NPCT 9.82%
- PRQR N/A
- EPS Growth
- NPCT N/A
- PRQR N/A
- EPS
- NPCT N/A
- PRQR N/A
- Revenue
- NPCT N/A
- PRQR $20,506,357.00
- Revenue This Year
- NPCT N/A
- PRQR $215.61
- Revenue Next Year
- NPCT N/A
- PRQR $71.92
- P/E Ratio
- NPCT N/A
- PRQR N/A
- Revenue Growth
- NPCT N/A
- PRQR 306.68
- 52 Week Low
- NPCT $8.58
- PRQR $1.61
- 52 Week High
- NPCT $10.63
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- NPCT 37.48
- PRQR 36.55
- Support Level
- NPCT $10.39
- PRQR $2.18
- Resistance Level
- NPCT $10.52
- PRQR $2.49
- Average True Range (ATR)
- NPCT 0.12
- PRQR 0.20
- MACD
- NPCT 0.02
- PRQR -0.01
- Stochastic Oscillator
- NPCT 37.67
- PRQR 29.69
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.